Laurus Labs
Laurus Labs Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Laurus Labs Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Laurus Labs Ltd trades at a P/E of 82.86× and P/B of 13.94×.
Valuation
Profitability
Growth
Financial Health
Laurus Labs Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Laurus Labs Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Laurus Labs Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Laurus Labs Ltd, switchable between annual and quarterly views, consolidated or standalone.
Laurus Labs Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹76,184.56 Cr and reported EPS of ₹16.52.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,069 | 2,292 | 2,832 | 4,814 | 4,936 | 6,041 | 5,041 | 5,554 | 6,813 |
| Other Income | 29 | 16 | 6 | 24 | 15 | 6 | 26 | 75 | 55 |
| Total Income | 2,098 | 2,308 | 2,838 | 4,837 | 4,951 | 6,047 | 5,067 | 5,629 | 6,868 |
| Cost of Goods Sold (COGS) | 1,064 | 1,236 | 1,413 | 2,158 | 2,194 | 2,774 | 2,432 | 2,478 | 2,695 |
| Gross Profit | 1,005 | 1,056 | 1,418 | 2,655 | 2,742 | 3,266 | 2,608 | 3,076 | 4,117 |
| +Operating Expenses | 592 | 700 | 854 | 1,105 | 1,319 | 1,674 | 1,831 | 2,021 | 2,340 |
| EBITDA | 413 | 356 | 565 | 1,551 | 1,422 | 1,592 | 778 | 1,055 | 1,778 |
| +Non-Operating Expenses | 205 | 252 | 277 | 273 | 354 | 489 | 567 | 646 | 651 |
| Profit Before Tax (PBT) | 237 | 120 | 294 | 1,301 | 1,084 | 1,109 | 236 | 484 | 1,182 |
| +Tax Expense | 70 | 26 | 38 | 317 | 251 | 312 | 68 | 130 | 292 |
| Profit After Tax (PAT) | 168 | 94 | 255 | 984 | 832 | 793 | 162 | 358 | 890 |
| Earnings Per Share (EPS) | 3.16 | 1.76 | 4.78 | 18.33 | 15.40 | 14.67 | 2.98 | 6.64 | 16.46 |
| Diluted Shares Outstanding (Nos.) | 53 | 53 | 53 | 54 | 54 | 54 | 54 | 54 | 54 |
| +Additional Disclosures | 2,925 | 3,420 | 3,946 | 5,699 | 6,066 | 7,706 | 7,256 | 7,623 | 8,377 |
| Sales Growth % | — | 10.77 | 23.55 | 69.99 | 2.54 | 22.39 | -16.55 | 10.18 | 22.67 |
| YoY Sales Growth % | — | 10.77 | 23.55 | 69.99 | 2.54 | 22.39 | -16.55 | 10.18 | 22.67 |
| Material Cost % | 51 | 54 | 57 | 49 | 46 | 43 | 48 | 44 | 41 |
| Employee Cost % | 12 | 13 | 12 | 9 | 10 | 10 | 13 | 13 | 13 |
| Other Cost % | 16 | 18 | 18 | 14 | 17 | 18 | 24 | 23 | 21 |
| OPM % | 20 | 16 | 20 | 32 | 29 | 26 | 15 | 19 | 26 |
| Tax % | 29 | 22 | 13 | 24 | 23 | 28 | 29 | 27 | 25 |
| Profit Growth % | — | -44.06 | 172.25 | 285.40 | -15.41 | -4.66 | -79.55 | 120.83 | 148.41 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 288 | 192 | 377 | 1,346 | 1,171 | 1,268 | 393 | 625 | 1,298 |
Laurus Labs segment analysis: revenue and profit mix.
Disclosed business segments at Laurus Labs with their share of revenue and profit, switchable between consolidated and standalone reporting.
Laurus Labs discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Laurus Labs Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Laurus Labs Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Laurus Labs Ltd's investment case rests on 7 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Laurus Labs demonstrates robust quarterly sales growth, with a significant 35.10% increase in the latest quarter. This indicates strong market demand and effective sales strategies, suggesting a healthy growth trajectory for the company.
The company reported an exceptional 883.00% increase in quarterly profit, signaling substantial improvements in profitability. This strong performance highlights effective operational management and potential for sustained future growth.
Laurus Labs maintains a healthy operating profit margin (OPM) of 23.40%, showcasing efficient cost management and strong pricing power within its industry. This robust profitability is a key indicator of financial health.
Foreign Institutional Investors (FIIs) have increased their holding from 22.67% to 26.17% since Sep 2022, alongside DIIs increasing from 9.34% to 11.72%. This rising institutional confidence is a positive sign.
The pharmaceutical sector, where Laurus Labs operates, is poised for sustained growth driven by increasing global healthcare expenditure, rising demand for generics, and advancements in drug discovery and development.
What can break it.
The company's high P/E ratio of 75.80 suggests a premium valuation compared to many industry peers, potentially indicating that the stock is overvalued. This could limit future upside if earnings growth slows down.
Laurus Labs exhibits a relatively low Return on Capital Employed (ROCE) of 9.15% and Return on Equity (ROE) of 7.45%, which are significantly below most industry peers. This indicates less efficient capital utilization.
Promoter holding stands at a relatively low 27.60%, which could be a concern for some investors regarding long-term commitment and corporate governance. A higher stake often signals stronger leadership confidence.
The stock has shown significant volatility, with a 52-week range from ₹474.00 to ₹973.00. This wide fluctuation presents considerable risk for investors seeking stable returns and could deter risk-averse capital.
Laurus Labs faces intense competition from larger, well-established players like Sun Pharma and Divi's Lab, which boast higher market caps and often superior profitability metrics, potentially limiting market share growth.
What would change my mind.
Trim if P/E re-rates above 108. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 46.87. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 13%. The operating engine is no longer compounding capital efficiently.
Laurus Labs Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Laurus Labs Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Laurus Labs Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Laurus Labs Ltd — derived from the live tape, not yesterday's close.
Laurus Labs Ltd last traded at ₹1,412.9 with an intraday range of ₹1,363.8–₹1,424.6 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1412.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1558.67 | +145.77 | +10.32% |
| R3 | 1497.87 | +84.97 | +6.01% |
| R2 | 1461.23 | +48.33 | +3.42% |
| R1 | 1437.07 | +24.17 | +1.71% |
| PIVOT | 1400.43 | -12.47 | -0.88% |
| CURRENT | 1412.90 | — | — |
| S1 | 1254.67 | -158.23 | -11.20% |
| S2 | 1315.47 | -97.43 | -6.90% |
| S3 | 1339.63 | -73.27 | -5.19% |
| S4 | 1376.27 | -36.63 | -2.59% |
LAURUSLABS is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 1363.8 ~ 1384.2
Trading Above opening range, showing Bullishness
Laurus Labs Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Laurus Labs Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Laurus Labs Ltd stood at 44.5% of traded volume, against a 20-day average of 53.8%.
Laurus Labs announcements: results, concalls, ratings, M&A.
Filings Laurus Labs sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Laurus Labs files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 127 documents below.
Copy of Newspaper Publication
Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication
Updates
Laurus Labs Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'.
Shareholders meeting
Laurus Labs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 02, 2026
Copy of Newspaper Publication
Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication
Disclosure under SEBI Takeover Regulations
Laurus Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange Board of…
Investor decks & rating reports.
Laurus Labs dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Laurus Labs has declared, sequenced by announce and record date.
Laurus Labs corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Laurus Labs Ltd: business, sector, key facts.
What Laurus Labs Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Laurus Labs Ltd operates in the Healthcare, listed as NSE: LAURUSLABS, BSE: 540222.
Laurus Labs Limited is a prominent Indian pharmaceutical company specializing in the manufacturing and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs) globally. Their core business revolves around providing generic APIs and oral solid dosage forms across a diverse range of therapeutic areas. This includes crucial medications for conditions such as HIV/AIDS (anti-retrovirals), diabetes, cardiovascular diseases, asthma, ophthalmic issues, cancer (oncology), gastrointestinal problems, and Hepatitis C.
The company's API production caters to a wide spectrum of therapeutic needs, demonstrating a strong commitment to addressing various healthcare challenges. Their focus on generics allows them to offer cost-effective alternatives to brand-name medications, increasing accessibility to essential medicines both domestically and internationally. This strategy contributes significantly to Laurus Labs' market position and competitive advantage.
Beyond APIs and finished formulations, Laurus Labs extends its expertise into the realm of biotechnology services. This diversification allows them to leverage their scientific capabilities in areas such as nutraceuticals, dietary supplements, alternative food proteins, and cosmeceuticals. The company's involvement in these fields showcases a forward-looking approach to expanding its product portfolio and tapping into emerging market segments.
Furthermore, Laurus Labs is engaged in the development of innovative enzymatic solutions for industrial biotechnology applications. This highlights their commitment to research and development, driving technological advancements within the broader biotechnology sector. Their work with animal origin-free recombinant proteins and enzymes for biopharmaceuticals signifies a dedication to producing high-quality, safe, and ethically sourced products for the pharmaceutical industry.
Finally, Laurus Labs offers comprehensive business support services specifically targeted at the pharmaceutical industry. The nature of these services isn't explicitly detailed but likely includes functions such as regulatory support, logistics, and potentially contract manufacturing or research collaborations. This completes their business model, rounding out their offerings with crucial support functions that strengthen their overall position within the pharmaceutical ecosystem.
Questions investors ask about Laurus Labs Ltd (LAURUSLABS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Laurus Labs Ltd (LAURUSLABS)?
The current share price of Laurus Labs Ltd (LAURUSLABS) is ₹1,412.9. Today, the stock has gained by ₹44.10 (3.22%), trading in a range of ₹1,363.8 to ₹1,424.6. The stock opened at ₹1,368 with a trading volume of 23,49,174 shares.
02Is Laurus Labs Ltd stock a good investment for long-term?
Laurus Labs Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹76,184.56 crores, P/E ratio of 82.86, ROE of 17.74%, and ROCE of 9.15%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Laurus Labs Ltd stock?
The 52-week high price of Laurus Labs Ltd (LAURUSLABS) is ₹1,457, while the 52-week low is ₹641.05. Currently trading at ₹1,412.9, the stock is 94.6% away from its 52-week low and 3.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Laurus Labs Ltd stock at the current price?
Whether to buy Laurus Labs Ltd stock at ₹1,412.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 82.86 and P/B ratio of 13.94. Today's performance shows a gain of 3.22%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Laurus Labs Ltd and when is the next dividend?
Laurus Labs Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,412.9, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Laurus Labs Ltd?
Laurus Labs Ltd's key financial metrics include: P/E Ratio: 82.86, P/B Ratio: 13.94, ROE: 17.74%, ROCE: 9.15%, Dividend Yield: 0.00%, EPS: ₹16.52, Book Value: ₹98.16, and Debt-to-Equity: 46.37. The company's market cap stands at ₹76,184.56 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Laurus Labs Ltd stock performing today in the market?
Laurus Labs Ltd stock opened at ₹1,368 and is currently trading at ₹1,412.9, showing a gain of ₹44.10 (3.22%). The intraday high is ₹1,424.6 and low is ₹1,363.8. The trading volume stands at 23,49,174 shares, indicating strong market participation today.
08What is the P/E ratio of Laurus Labs Ltd and what does it indicate?
Laurus Labs Ltd has a Price-to-Earnings (P/E) ratio of 82.86, which means investors are willing to pay ₹82.86 for every ₹1 of earnings. With an EPS of ₹16.52, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Laurus Labs Ltd (LAURUSLABS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy